Solar Energy for Pharmaceutical Plants in India

Key Takeaways

• India is the world's 3rd largest pharmaceutical producer by volume and a leading generic drug exporter — the sector runs continuous, power-intensive operations at drug manufacturing facilities across Hyderabad, Ahmedabad, Baddi, Vapi, Ankleshwar, and Panipat
• Electricity accounts for 15–20% of total operating costs in pharmaceutical manufacturing — dominated by HVAC (air handling units, cleanroom conditioning), refrigeration, compressed air, utilities, and process equipment
• HVAC and cleanroom conditioning typically represent 40–60% of total facility electricity consumption — the largest single load in most pharmaceutical plants, running continuously 24/7
• A 500 kW rooftop solar system at a mid-size formulations plant in Gujarat or Haryana can save approximately ₹45–65 lakh per year at prevailing HT industrial tariffs while reducing Scope 2 carbon emissions
• Grid-tied solar does not compromise power continuity — pharmaceutical-grade installations pair solar with online UPS systems; the grid remains the backup at all times; there is zero disruption risk to cleanroom environments
• Open access solar is increasingly used by large pharma companies (contract research and manufacturing services / CRAMS players, bulk API manufacturers) with monthly consumption above 5 lakh units

India's pharmaceutical sector is one of the most energy-demanding manufacturing industries. Unlike automobile plants or metal fabricators that can run on two or three shifts, pharmaceutical manufacturing — particularly API (Active Pharmaceutical Ingredient) synthesis and sterile formulations — operates around the clock. Reactors, HVAC, cleanrooms, refrigeration, analytical labs, and effluent treatment plants never fully switch off.

This continuous, high-load operation makes electricity a critical cost line item. At ₹8–11/unit from DISCOM in India's main pharma states (Telangana, Gujarat, Himachal Pradesh, Haryana), a 5 MW connected load facility spends ₹3–5 Cr/month on electricity. For pharma plant owners and CFOs looking to structurally reduce operating costs, solar is increasingly the first lever.

Energy Profile of Pharmaceutical Manufacturing

1. HVAC and Cleanroom Conditioning (40–60% of total load)

This is the dominant load in virtually every pharmaceutical plant. Current Good Manufacturing Practice (cGMP) requirements mandate strict environmental controls:

• Temperature: typically 20–25°C for most manufacturing areas; 15–20°C for API synthesis; 2–8°C cold storage
• Relative humidity: 45–65% for most solid dosage forms; below 25% for moisture-sensitive products
• Pressure differentials: positive pressure in cleanrooms to prevent contamination
• Air change rates: 20–60 air changes per hour (ACH) in cleanrooms vs 6–8 ACH in standard industrial spaces

Meeting these requirements requires Air Handling Units (AHUs), chillers, cooling towers, dehumidifiers, and variable air volume (VAV) systems running continuously. A 10,000 sq metre formulations plant may have 500–1,500 kW in HVAC loads alone.

2. Compressed Air (10–15% of total load)

Pharmaceutical manufacturing requires oil-free compressed air for:

• Pneumatic conveying of powders (filling lines)
• Tablet compression and coating
• Sterile area pressurisation
• Process instrument control
• Granulation and blending

Oil-free compressors (required by cGMP) are less efficient than standard compressors; compressed air generation typically accounts for 10–12% of facility electricity.

3. Process Equipment (15–25% of total load)

• Reactors and distillation (API plants): Heating and agitation — high energy per batch; electric immersion heaters or steam from electric boilers
• Tablet presses, capsule filling machines, coating drums: 30–200 kW per line
• Autoclaves and sterilisation (injectable plants): 50–300 kW per autoclave (steam/electrical)
• Lyophilisers (freeze dryers): 50–500 kW per unit — the most energy-intensive single piece of equipment in sterile manufacturing
• Fermenters (biotech/fermentation plants): 100–800 kW per fermenter

4. Refrigeration and Cold Chain (10–20% of total load)

• Refrigerated storage for biologics, vaccines, and temperature-sensitive APIs
• Cold rooms: 2–8°C (pharmaceutical), -20°C (frozen plasma, biologics), -80°C (deep freeze)
• Cold chain logistics staging areas
• A large biotech plant may have 500–2,000 kW of dedicated refrigeration

5. Laboratory and Utilities (10–15% of total load)

• Analytical labs (HPLC, GC, spectrometry): 30–200 kW per lab building
• Water For Injection (WFI) generation: Multi-effect distillation or reverse osmosis + ultrafiltration: 50–300 kW
• Effluent Treatment Plant (ETP): 50–500 kW depending on capacity and effluent load

Why Solar Is Suitable for Pharma Plants

Daytime HVAC Load Alignment

HVAC and cooling systems run 24/7 — but their peak demand occurs during the day, when ambient temperatures are highest and cooling demand peaks. This aligns precisely with solar generation. A pharma plant in Hyderabad or Ahmedabad can typically offset 40–60% of its HVAC electricity with rooftop solar, reducing the facility's largest cost driver significantly.

Large, Accessible Rooftops

Pharmaceutical plants — especially formulations facilities and general pharma warehouses — are built in single-storey or two-storey industrial format with large, flat rooftops. An 8,000 sq metre plant has rooftop space for 600–800 kW of solar.

No Power Interruption Risk

Grid-tied solar systems synchronise seamlessly with the DISCOM supply. When solar output drops (cloud, evening), the grid picks up instantly. Solar installation does not create any power interruption risk — critical for pharmaceutical plants where grid-supply continuity is essential for cleanroom integrity and batch consistency.

For truly uninterruptible processes (sterile filling, lyophilisation), existing online UPS systems already handle the grid + solar transition invisibly. Solar is simply a lower-cost input layer beneath the existing power infrastructure.

cGMP Compliance Is Unaffected

Solar installations on pharmaceutical facilities must consider:

• Roof penetration for mounting structures (coordinate with facility structural engineer and leak testing)
• Electrical installation quality (IEC 61439-1 compliant switchgear, proper earthing)
• Pest control (sealed cable management to prevent rodent ingress)
• Housekeeping (panel cleaning does not use chemicals that could contaminate manufacturing areas)

None of these are obstacles — they are standard considerations for any industrial solar installation on a cGMP-classified facility.

System Sizing for Pharmaceutical Plants

Small Formulations Plant (solid dosage, 50 million tablets/year):

• Monthly electricity consumption: 1.5–3 lakh units
• Available rooftop: 30,000 sq ft
• Recommended system: 200–350 kW
• Annual savings at ₹8.50/unit: approximately ₹22–36 lakh
• CAPEX: ₹80 lakh–₹1.4 Cr
• Payback: approximately 3.5–4.5 years

Mid-Size Formulations Plant (solid + liquid oral dosage, 200 million tablets/year + liquid):

• Monthly electricity consumption: 5–10 lakh units
• Available rooftop: 80,000 sq ft (manufacturing building + warehouse)
• Recommended system: 600 kW–1 MW
• Annual savings at ₹9/unit: approximately ₹65 lakh–₹1.08 Cr/year
• CAPEX: ₹2.4–3.8 Cr
• Payback: approximately 3–4 years

Large API Manufacturing Plant (continuous synthesis):

• Monthly electricity consumption: 20–60 lakh units
• Suitable approach: Open Access Solar from an off-site plant; rooftop supplemented by open access supply
• Landed solar cost via open access: ₹4.00–5.50/unit (vs ₹9–11/unit DISCOM)
• Annual savings on 30 lakh units/month open access: approximately ₹15–21 Cr/year
• This represents a direct 5–7% improvement in operating margin for a typical API plant

Figures are indicative for 2026 EPC costs and DISCOM tariffs.

CAPEX vs RESCO vs Open Access for Pharma Companies

CAPEX Solar

For mid-to-large pharmaceutical companies — Sun Pharma, Dr. Reddy's, Cipla, Aurobindo, Divi's Laboratories, Granules India, and their contract manufacturing partners — CAPEX solar with 40% accelerated depreciation in Year 1 provides:

• Direct electricity cost savings from Day 1
• Additional tax shield in Year 1 (40% of CAPEX deducted against profit)
• Asset on books depreciating over 5–8 years for accounting purposes
• Full 25-year benefit accruing to the company

RESCO / PPA

For smaller pharma companies or those wary of capital deployment on non-core infrastructure, the RESCO model provides immediate savings without upfront investment. The EPC company funds and owns the solar system; the pharma plant buys solar electricity at 15–25% below DISCOM rates.

Open Access Solar

For large API manufacturers with monthly consumption above 15–20 lakh units, open access solar from nearby utility-scale projects is the most cost-effective option. Electricity lands at ₹4.00–5.50/unit including all charges — versus ₹9–11/unit from DISCOM for HT industrial consumers in Telangana, Gujarat, or Haryana.

For India's bulk pharmaceutical chemical (BPC) clusters — Hyderabad's Genome Valley, Gujarat's Vapi-Ankleshwar corridor, Baddi in Himachal Pradesh, Panipat in Haryana — open access solar through group captive arrangements is the dominant model for large energy consumers.

State-Specific Considerations for India's Pharma Clusters

Telangana (Hyderabad, Genome Valley):

• TSSPDCL/TSNPDCL HT industrial tariff: approximately ₹8.50–9.50/unit (FY 2026)
• Open access CSS: relatively low in Telangana; group captive is cost-effective
• Excellent solar irradiation (5.5 peak sun hours/day)
• A 1 MW solar installation saves approximately ₹90–95 lakh/year at Telangana rates

Gujarat (Vapi, Ankleshwar, Ahmedabad):

• DGVCL/MGVCL HT tariff: approximately ₹8.0–9.0/unit (FY 2026)
• Gujarat has strong open access policy; CSS is moderate; banking allowed (extended June 30, 2026)
• Best solar resource in India outside Rajasthan (5.5–6.0 peak sun hours/day in south Gujarat)
• A 500 kW system in Vapi generates approximately 7.5–8 lakh units/year

Himachal Pradesh (Baddi):

• Baddi pharma cluster: HP State Electricity Board HT tariff approximately ₹6.50–7.50/unit
• Mountainous terrain limits flat rooftop solar potential; most installations are ground-mount on factory premises
• Lower tariffs mean slightly longer payback periods vs Gujarat or Telangana

Haryana (Panipat, Bahadurgarh, Sonipat):

• DHBVN/UHBVN HT tariff: approximately ₹8.50–9.50/unit (FY 2026)
• HERC open access charges are moderate; group captive from Rajasthan solar is increasingly common for large Haryana pharma consumers
• Proximity to Delhi-NCR makes Sun Wave Technologies an ideal EPC partner for Haryana pharma plants

For a full open access cost comparison by state: Solar Open Access Costs by State: India 2026 Comparison.

ALMM List-II Compliance (June 2026)

From June 1, 2026, all solar modules used in grid-connected systems in India must comply with ALMM List-II (using domestically manufactured solar cells). For pharmaceutical companies:

• Request ALMM compliance certificates from your EPC contractor at proposal stage
• This is a mandatory regulatory requirement — non-compliant modules cannot legally connect to the DISCOM grid or qualify for open access
• Approved module brands include Waaree, Adani Solar, Vikram Solar, RenewSys, Tata Power Solar, and others listed under ALMM List-I
• ALMM compliance adds approximately 2–5% to module cost in 2026 — negligible relative to total project cost

Solar and Sustainability in Pharma: ESG and Scope 2 Targets

Pharmaceutical companies face growing pressure from:

• Global supply chain customers (especially US, EU, and Japan pharma buyers): ESG audits increasingly include Scope 2 electricity emissions in supplier assessments
• SEBI BRSR (Business Responsibility and Sustainability Reporting): Listed Indian pharma companies must disclose energy consumption and Scope 2 emissions in annual reports
• Science Based Targets initiative (SBTi): Several large Indian pharma companies have committed to SBTi-aligned targets, including Scope 2 reduction through renewable electricity procurement

Solar electricity — whether rooftop or open access — is the most direct and cost-effective way to reduce Scope 2 emissions for a manufacturing facility. A 1 MW solar plant generating 15 lakh units/year displaces approximately 1,230 tonnes of CO2 per year (at CEA emission factor 0.82 kgCO2/kWh for FY 2024-25).

For the largest pharma companies, open access solar combined with Renewable Energy Certificates (RECs) provides both the physical renewable energy and the tradable certificate for compliance and reporting purposes.

For more on RECs: Solar RECs: How Indian Factories Trade Green Certificates.

The Bottom Line: Solar ROI for Pharma Plants

The financial case for solar at pharmaceutical manufacturing facilities is straightforward and compelling:

• A 1 MW rooftop solar installation at a Hyderabad pharma plant saves approximately ₹1.0–1.2 Cr per year at Telangana HT tariffs — a direct addition to operating margin
• Payback period is 3–4 years for CAPEX solar at current EPC costs and tariff levels; accelerated depreciation improves this to 2–2.5 years for profitable companies
• Open access solar for large API plants can save ₹5–20 Cr per year depending on plant size — a transformation in cost structure for energy-intensive API synthesis operations
• Solar electricity has zero fuel cost risk — unlike grid tariffs (which have increased 6–10% annually in most states over the past decade), solar cost is fixed at installation and declines over the project's 25-year life

For pharmaceutical plant operators, the question is not whether solar makes sense — it demonstrably does. The question is which model best fits your plant's consumption profile, ownership structure, and capital allocation policy.

How Sun Wave Technologies Serves Pharma Plants

Sun Wave Technologies designs and installs industrial solar systems for manufacturing facilities across Delhi-NCR, Haryana, Rajasthan, UP, Gujarat, and Maharashtra. For pharmaceutical clients, our approach includes:

• Detailed load profile analysis — understanding HVAC cycling, lab schedules, production shift patterns to right-size the solar system for maximum self-consumption
• Structural compatibility assessment — coordinate with facility structural consultant for cleanroom rooftops; solar mounting on pharma facility roofs requires careful planning around ventilation stacks, AHU exhausts, and HVAC equipment
• ALMM-compliant procurement and EPC execution
• RESCO / Zero-CAPEX structuring for pharma companies preferring off-balance-sheet solar
• Open access consultation and project facilitation for large pharma consumers in eligible states

To start: How to Choose a Solar EPC Company in India.

Frequently Asked Questions

Q: Can solar power pharmaceutical cold storage (2–8°C)? Yes. Cold storage refrigeration compressors (typically 50–500 kW) run during the day and are an excellent solar load. Grid-tied solar offsets the compressor electricity cost during daylight hours; the grid maintains supply at night and during cloud cover. The cold storage temperature is maintained continuously — solar integration creates no temperature disruption.

Q: Will solar installation compromise our cGMP certification? No. cGMP (under Schedule M / 21 CFR for US FDA-approved plants) governs manufacturing processes, environmental controls, documentation, and equipment validation — not the power source. Solar electricity is equivalent to grid electricity for all cGMP purposes. Many WHO-GMP, ISO 15378, and US FDA-inspected pharma plants globally have solar installations with no impact on GMP status.

Q: Our plant requires 24/7 uninterrupted power for critical processes. Is solar suitable? Grid-tied solar does not affect power continuity — the grid remains your primary supply and seamlessly takes over whenever solar output is insufficient. Your existing UPS/DG backup systems remain in place. Solar reduces daytime grid import without creating any interruption risk. Pharmaceutical plants running lyophilisers, sterile filling lines, or continuous API reactors can safely adopt grid-tied solar.

Q: What is the typical solar installation for a WHO-GMP formulations plant in Baddi? Baddi plants face specific constraints: mountainous terrain, less direct sunlight than flat plains locations, and narrower rooftops on multi-storey factory buildings. A typical WHO-GMP plant in Baddi with 50,000 sq ft of usable rooftop can install 200–350 kW of solar, generating 2.5–4.5 lakh units/year and saving ₹18–34 lakh/year at HP tariffs.

Q: Can our pharma plant's solar installation be counted toward BRSR sustainability reporting? Yes. Solar electricity consumed on-site (rooftop solar) reduces your organisation's Scope 2 emissions. Open access solar from ALMM-certified renewable plants also reduces Scope 2 emissions. Both can be disclosed in BRSR (Business Responsibility and Sustainability Report) as renewable energy consumption, reducing your electricity-sourced GHG intensity. For market-based Scope 2 accounting, pairing solar with RECs provides the most robust disclosure.

Q: Is there any risk of contamination from solar panel cleaning chemicals near our manufacturing areas? Standard solar panel cleaning uses deionised water or mild soap solutions — not harsh chemicals. For pharma facilities where any chemical contamination risk is unacceptable, panels can be cleaned using pure water cleaning systems. Cleaning staff work on rooftops only; there is no contact with manufacturing areas. Proper bund drains and panel mounting orientation ensure cleaning water drains away from HVAC fresh air intakes. These are standard pharma-site solar installation considerations — not obstacles.

Q: How does solar interact with our diesel gensets for backup power? Grid-tied solar operates independently of your diesel gensets. During normal operation, solar and grid supply the load; gensets are in standby. During a grid failure, standard grid-tied solar inverters shut down (anti-islanding protection). If you want solar to also operate during grid outages, a Solar + BESS (battery storage) system with island mode capability can be designed. For pharma plants, this adds cost but can reduce DG runtime significantly.

Sources

• GoSmartRoof — Solar for Pharma and Chemical Industries India: gosmartroof.com
• WorldPharmaToday — Solar Energy in Pharma: A Sustainable Future: worldpharmatoday.com
• TotalEnergies Asia — Meeting Pharma's Net-Zero Goals Through Solar Innovation: totalenergies.asia
• Central Electricity Authority (CEA) — CO2 Baseline Emission Factor FY 2024-25 (0.82 kgCO2/kWh)
• MNRE ALMM List-II Implementation (June 1, 2026)
• SEBI BRSR Framework (FY 2023-24 onwards, mandatory for top 1,000 listed companies)